Business
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
SAN DIEGO, May 11, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 2026.
About this update from Contineum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/53e4730f217188a7610fa5907d86f338"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LWx0cKTFzhKj70CezpyWJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOQ--/https://media.zenfs.com/en/business-wire.com/53e4730f217188a7610fa5907d86f338","width":960,"height":339},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/089jTkXiVDY1_7_w3wAMZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIyNg--/https://media.zenfs.com/en/business-wire.com/53e4730f217188a7610fa5907d86f338","width":640,"height":226},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4rWhLTFyv9y9CUwCw_vYZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg-/https://media.zenfs.com/en/business-wire.com/53e4730f217188a7610fa5907d86f338","width":1200,"height":424}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 11, 2026--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 2026.","length":516,"tagName":"p"},{"type":"text","content":"The following abstracts are posted on ATS 2026’s online itinerary planner for registered users.","length":95,"tagName":"p"},{"type":"text","content":"Title: PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists With Distinct Lung Occupancy Profiles and Vascular EffectsPresenter: Daniel S. Lorrain, Ph.D., Chief Scientific Officer at Contineum TherapeuticsPoster: P155Date and Time: Monday, May 18, 2026 from 11:30 a.m. ET-1:15 p.m. ETSession: From Target Discovery to Clinical Translation in Pulmonary Fibrosis","length":392,"tagName":"p"},{"type":"text","content":"Title: LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In VitroPresenter: Michael Poon, Ph.D., VP, Biology at Contineum TherapeuticsPoster: P156Date and Time: Monday, May 18, 2026 from 11:30 a.m. ET-1:15 p.m. ETSession: From Target ...